

## **DSM Pharmaceutical Products**

45 Waterview Blvd  
Parsippany, NJ 07054-1298

### **DSM Is the Winner of the Silver CPhI Innovation Award**

(Parsippany – October 4, 2007)

DSM Pharmaceutical Products, a leading provider of contract development and manufacturing services is pleased to announce today DSM has been awarded the Silver, CPhI Innovation Award. DSM Pharmaceutical Products has won the Silver Award for their work on the use of MonoPhos™ ligands in asymmetric hydrogenations. The CPhI Innovation Award has been established as the showcase for exceptional work in developing research and technology. The CPhI Innovation Awards are setting the standards for the pharmaceutical manufacturing industry.

The MonoPhos™ family of ligands has improved the methodology that is used to prepare a wide range of chiral molecules in high yield and with excellent selectivity. The DSM ligands, unlike more traditional ligands used for asymmetric hydrogenations, can be produced in fewer steps, thus reducing production time. In addition, their ability to mix and match allows for a greater chance of diversity, not currently seen with traditional families of ligands.

The DSM methodology, allows for a more efficient procedure from synthesis of the ligand through commercial production, while decreasing costs.

Ronald Gebhard, R&D Director, DSM Pharmaceutical Products, comments, "The DSM approach is like playing on the majority of numbers at a roulette table, the chances of winning are greatly increased compared to playing just one number."

This methodology has been integrated from research, into commercial production and is currently being used at the DSM's large scale manufacturing facility located in Linz, Austria.

Johannes de Vries, DSM Principal Scientist Homogeneous Catalysis, comments, "The use of MonoPhos™ ligands is not only limited for large-scale asymmetric hydrogenations. In collaboration with the University of Groningen we are investigating other exciting applications of catalysts including the formation of carbon-carbon bonds to generate a new chiral center with high selectivity."

### **About DSM Pharmaceutical Products**

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products.

From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers' unique manufacturing needs.

## **About DSM**

DSM is active worldwide in [nutritional and pharma ingredients, performance materials and industrial chemicals](#). The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named [Vision 2010 – Building on Strengths](#), focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with [locations](#) in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at [www.dsm.com](http://www.dsm.com).

## **Forward-looking statements**

*This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.*

## **For more information:**

### **DSM Pharmaceutical Products**

Dr. Ronald Gebhard  
Director Research & Development  
+31 46 4761514  
[ronald.gebhard@dsm.com](mailto:ronald.gebhard@dsm.com)